2009 Nhamcs Micro-Data File Documentation Page 1

Total Page:16

File Type:pdf, Size:1020Kb

2009 Nhamcs Micro-Data File Documentation Page 1 2009 NHAMCS MICRO-DATA FILE DOCUMENTATION PAGE 1 ABSTRACT This material provides documentation for users of the public use micro-data files of the 2009 National Hospital Ambulatory Medical Care Survey (NHAMCS). NHAMCS is a national probability sample survey of visits to hospital outpatient and emergency departments, conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. The survey is a component of the National Health Care Surveys, which measure health care utilization across a variety of health care providers. There are two micro-data files produced from NHAMCS, one for outpatient department records and one for emergency department records. Section I of this documentation, “Description of the National Hospital Ambulatory Medical Care Survey,” includes information on the scope of the survey, the sample, field activities, data collection procedures, medical coding procedures, and population estimates. Section II provides detailed descriptions of the contents of each file’s data record by location. Section III contains marginal data for selected items on each file. The appendixes contain sampling errors, instructions and definitions for completing the Patient Record forms, and lists of codes used in the survey. PAGE 2 2009 NHAMCS MICRO-DATA FILE DOCUMENTATION SUMMARY OF CHANGES FOR 2009 The 2009 NHAMCS Emergency Department and Outpatient Department public use micro-data files are, for the most part, similar to the 2008 files, but there are some important changes. These are described in more detail below and reflect changes to the survey instrument, the Patient Record form. Emergency Departments 1. New or Modified Items a. In item 1, Patient Information, there is a new checkbox item “Arrival by Ambulance.” This replaces the 2008 item, “Mode of Arrival.” b. In item 2, Triage, there are new items for: On Oxygen Glasgow Coma Scale (3-15) c. It should be noted that in item 1a. Date and Time of Visit, the “Seen by “ category was expanded from “Date and Time Seen by Physician” to “Date and Time Seen by MD/DO/PA/NP” (i.e., Doctor of Medicine, Doctor of Osteopathy, Physician Assistant, or Nurse Practitioner). Although actual “Seen by” times are not included on the public use file, these times are used in conjunction with arrival times to produce WAITTIME (waiting time to see the MD/DO/PA/NP) on the public use file. d. Data users should also note that, although Triage level (item 2b) is now asked using a 1-5 level scale on the Patient Record form, answers to this item have been edited in conjunction with responses from the hospital induction interview. Because some hospitals use different scales for triage, it was necessary to take that information into account when interpreting results in item 2b. Also, some emergency service areas (ESAs) do not use a nursing triage system. Missing values for item 2b for ESAs that do use nursing triage systems were imputed using a hot deck as described in Section 1. Results for the Triage item are presented on the public use file with the same categories used in previous years of NHAMCS: immediate, emergent, urgent, semi-urgent, and nonurgent. The variable name is now IMMEDR rather than IMMED to emphasize the changes. e. Pain Scale (item 2c), with values from 0-10, replaces the former categorical variable, Presenting Level of Pain. f. The Record Format item formerly referred to as PAYTYPE has been renamed PAYTYPER in order to emphasize the fact that it is a recoded item based on the collection of multiple expected sources of payment. This is explained in more detail below. IMPORTANT: Both the NAMCS and NHAMCS Patient Record Forms collected primary expected source of payment at ambulatory care visits from 1997 through 2004. This variable, called PAYTYPE, was included on the Public Use Files for those years. When the NAMCS and NHAMCS Patient Record Forms were modified to collect multiple expected sources of payment starting in 2005, all expected sources of payment were included on the Public Use Files. In addition, in order to provide a proxy for primary expected source of payment, a recoded variable, was included. This variable, called PAYTYPE for consistency with earlier years, used a hierarchical scheme to recode the multiple source data into primary source. As noted in the public use file documentation for each year from 2005 through 2007, the top of the hierarchy was Medicaid, followed by Medicare, Private Insurance, Worker’s Compensation, Self Pay, No Charge/Charity, Other and Unknown. This was the hierarchy chosen by branch staff for use in 2005 through 2007. Medicaid was listed first because many researchers are interested in studying care among patients who are poor enough to be on Medicaid; however, data users could always take the original expected pay source data on the public use file and recode it according to their own preferred hierarchy. 2009 NHAMCS MICRO-DATA FILE DOCUMENTATION PAGE 3 In our analyses of emergency department trends from 1997 through 2007 using the PAYTYPE variable, we observed a distinct discontinuity between 2004, the last year that primary expected source of payment was collected, and 2005, when multiple sources of payment were recoded into a hierarchical variable. Our best interpretation of what we have observed results from the fact that the Medicaid-dominant hierarchy is inconsistent with insurance industry practices. Centers for Medicare & Medicaid Services (CMS) treats payment for services for persons who are beneficiaries of both Medicare and Medicaid (dual eligibles) by assigning Medicare as the primary source of payment. We recommend that when analyzing trends across these two time periods, researchers should keep in mind that two different methods were used to collect payment data, and that they may wish to recode PAYTPE in the 2005-2007 NAMCS and NHAMCS public use files to assign Medicare as the primary source of payment for dual eligibles. For 2008, NCHS recoded the PAYTYPE variable to more accurately reflect CMS practices, with Medicare at the top of the PAYTYPE hierarchy. This hierarchy has been continued in 2009. As an additional step, the variable name is being changed from PAYTYPE to PAYTYPER on the upcoming 2009 NAMCS and NHAMCS Public Use Files, to ensure that data users understand that this item is not the same as the primary expected source of payment data collected prior to 2005. In the near future, this name change will also be made to the 2008 NAMCS and NHAMCS Public Use File documentation for consistency with 2009. It is planned that the 2005-2007 NAMCS and NHAMCS Public Use Files will eventually be re-released to include a Medicare-dominant hierarchy for each year, in order to achieve a consistent version of PAYTYPER from 2005-2009. One other caveat regarding expected sources of payment and the hierarchical recode to a primary expected source of payment is this: Although those with both Medicare and private insurance are coded in PAYTYPER as having a primary expected payment source of Medicare, users should be advised that private insurance will be the primary payer for some individuals who are at least 65 years old, work full-time, and have employer-sponsored health insurance. g. In item 6, Provider’s Diagnosis for this Visit, a second section has been added, “Does patient have”, which includes checkboxes for 5 chronic conditions (cerebrovascular disease/history of stroke, congestive heart failure, condition requiring dialysis, HIV, and diabetes. h. In item 7, Diagnostic/Screening Services, there is a new checkbox for HIV test. j. In item 8, Procedures, there are new checkboxes for: Suturing/Staples Pelvic exam Central line j. In item 10, Providers, there are now checkboxes for: Consulting physician Mental health provider k. In item 12, Visit Disposition, there are new checkboxes for: Transfer to psychiatric hospital The previous checkbox for “Admit to observation unit” has been replaced by two more specific categories: Admit to observation unit, then hospitalized Admit to observation unit, then discharged PAGE 4 2009 NHAMCS MICRO-DATA FILE DOCUMENTATION l. In item 13, Hospital Admission, part a, “Admitted to:”, please note that the order of checkboxes #4 (mental health or detox unit) and #5 (cardiac catheterization lab) was switched on the Patient Record Form, relative to the order used in 2007 and 2008. The 2009 order was also used in 2010 and 2011. Prior to 2007, a smaller set of checkboxes was used (critical care unit, OR/cath lab, other bed/unit, unknown). Please keep these changes in mind when combining data across years or trending. m. In item 13, Hospital Admission, there is a new sub-item for Admitting Physician. Time data items have been modified to collect date and time bed was requested for hospital admission and date and time patient actually left the emergency department. n. Item 14, Observation Unit Stay asks about date of observation unit discharge. 2. Deleted Items a. In item 1, Patient Information, the categories for the sub-item on patient residence have been modified. The categories of “Other institution” and “Other residence” have been combined into a single “Other category. b. In item 1, Patient Information, the former “Mode of Arrival” sub-item has been deleted and replaced with “Arrival by Ambulance.” (See above.) c. In item 7, Diagnostic and Screening Services, the MRI sub-categories of “Head” and “Other than Head” have been removed. d. In item 8, Procedures, deleted checkbox categories include “Laceration repair,” “wound debridement,” and “NG tube/gastric suction.” e. In item 10, Providers, the category, “On-call attending physician/Fellow/Resident” has been deleted. f. In item 11, Visit Disposition, the category, “Refer to Social Services” has been deleted. Outpatient Departments 1. New or Modified Items a. In item 7, Diagnostic /Screening Services, there are new checkboxes for: Foot examination Retinal examination HIV test b.
Recommended publications
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • When to Consider Tubal Reversal Vs IVF Success Rates Point to Greater Outcomes with IVF for Women in Their Mid-Thirties and Older
    MEDICAL UPDATE When to Consider Tubal Reversal vs IVF Success Rates Point to Greater Outcomes with IVF for Women in their Mid-Thirties and Older Shady Grove Fertility has tapped Jason Bromer, M.D., to explore the two primary ways a reproductive endocrinologist (REI) can help achieve pregnancy after a tubal ligation: a tubal ligation reversal or in vitro fertilization (IVF). "Women with tubal ligations are some of our most successful patients because we know that they have been fertile before," explains Dr. Bromer. "In earlier days, tubal reversals were the traditional method of reestablishing a woman’s fertility. However, advancements in assisted reproductive technologies position IVF as a very viable option." 3 QUESTIONS TO ASK YOUR PATIENTS WITH TUBAL LIGATION ASK: What type of tubal ligation did you have? ASK: How soon do you want to have ASK: Do you have a new partner? WHY: The type of ligation performed (clipped, another child? WHY: "The majority of my patients seeking tubal cauterized, tied and cut) can indicate success rate WHY: It’s most common for women in their 30s ligation reversals already have children, but for tubal ligation reversal and IVF, depending on to pursue pregnancy following a tubal ligation. want one more child with a new partner," says Dr. the length and healthy tissue available. However, a woman’s ovarian reserve decreases Bromer. "IVF is almost always the better option in with age, with sharp declines at ages 35 and older. this case." TUBAL REVERSAL IVF • Ideal candidates are women under age 35 who had a • Ideal candidates are women with a good ovarian reserve.
    [Show full text]
  • Appendix on Tariff Elimination Schedule for Mercosur
    Trade part of the EU-Mercosur Association Agreement Without Prejudice Disclaimer: In view of the Commission's transparency policy, the Commission is publishing the texts of the Trade Part of the Agreement following the agreement in principle announced on 28 June 2019. The texts are published for information purposes only and may undergo further modifications including as a result of the process of legal revision. However, in view of the growing public interest in the negotiations, the texts are published at this stage of the negotiations for information purposes. These texts are without prejudice to the final outcome of the agreement between the EU and Mercosur. The texts will be final upon signature. The agreement will become binding on the Parties under international law only after completion by each Party of its internal legal procedures necessary for the entry into force of the Agreement (or its provisional application). AR applied BR applied PY applied UY applied Mercosur Final NCM Description Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 01022911 Other bovine animals for breeding,pregnant or lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 01023911 Other buffalo for breeding, ex.
    [Show full text]
  • New Therapeutic Property of Dimebon As a Neuroprotective Agent
    Send Orders for Reprints to [email protected] Current Medicinal Chemistry, 2016, 23, 1-12 1 REVIEW ARTICLE New Therapeutic Property of Dimebon as a Neuroprotective Agent Aleksey Ustyugov1, Elena Shevtsova1, George E. Barreto2,3, Ghulam Md Ashraf 4, Sergey O. Bachurin1 and Gjumrakch Aliev1,5,6,* 1Institute of Physiologically Active Compounds, Russian Academy of Sciences, Severniy Proezd 1, Cher- nogolovka, 142432, Russia; 2Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Uni- versidad Javeriana, Bogotá D.C., Colombia; 3Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile; 4King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Ara- bia; 5GALLY International Biomedical Research Consulting LLC., 7733 Louis Pasteur Drive, #330, San An- tonio, TX, 78229, USA; 6School of Health Science and Healthcare Administration, University of Atlanta, E. Johns Crossing, #175, Johns Creek, GA, 30097, USA Abstract: Dimebon (or Latrepirdine) was initially used as an anti-histamergic drug but later new therapeutic properties were rediscovered, adding to a growing body of “old” agents with prominent neuroprotective effects. In the present manuscript, we are focusing on our latest study on Dimebon with regard to brain’s pathological processes using in vivo protei- A R T I C L E H I S T O R Y nopathy models. In the study, neurodegenerative pathology has been attributed to a group of aggregate-prone proteins: hyperphosphorylated tau, fused in sarcoma and γ-synuclein , which Received: March 13, 2016 Revised: June 08, 2016 are involved in a number of neurological disorders. We have also presented our in vitro Accepted: July 24, 2016 model based on overexpression of an aberrant mutant form of transactive response DNA DOI: 10.2174/0929867323666160804 binding 43 kDa protein in cultured SH-SY5Y neuroblastoma cells.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Successful Pregnancies After Removal of Intratubal Microinserts
    2. Tonni G, De Felice C, Centini G, Ginanneschi C. Cervical and 5. Levine AB, Alvarez M, Wedgwood J, Berkowitz RL, Holzman oral teratoma in the fetus: a systematic review of etiology, I. Contemporary management of a potentially lethal fetal pathology, diagnosis, treatment and prognosis. Arch Gynecol anomaly: a successful perinatal approach to epignathus. Obstet Obstet 2010;282:355–61. Gynecol 1990;76:962–6. 3. Calda P, Novotna M, Cutka D, Brestak M, Haslik L, Goldova 6. Berrington JE, Stafford FW, Macphail S. Emergency EXIT for B, et al. A case of an epignathus with intracranial extension preterm labour after FETO. Arch Dis Child Fetal Neonatal Ed appearing as a persistently open mouth at 16 weeks and 2010;95:F376–7. subsequently diagnosed at 20 weeks of gestation. J Clin Ultra- 7. Hedrick HL, Flake AW, Crombleholme TM, Howell LJ, sound 2011;39:164–8. Johnson MP, Wilson RD, et al. The ex utero intrapartum 4. Marwan A, Crombleholme TM. The EXIT procedure: principles, therapy procedure for high-risk fetal lung lesions. J Pediatr pitfalls, and progress. Semin Pediatr Surg 2006;15:107–15. Surg 2005;40:1038–44. Successful Pregnancies After and who would like to conceive have two options: in vitro fertilization and sterilization reversal. Successful Removal of Intratubal Microinserts pregnancies resulting from in vitro fertilization after intratubal microinsert sterilization have been described.2 Charles W. Monteith, MD, Based on a literature search of the entire PubMed and Gary S. Berger, MD, MPH database up to August 2011 (using the key words “Essure” and “pregnancy”), these are the first two re- BACKGROUND: Patients with intratubal microinsert ports of successful pregnancy after surgical outpatient sterilization later may request reversal.
    [Show full text]
  • Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K
    HANDBOOK OF Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K. Niazi CRC PRESS Boca Raton London New York Washington, D.C. Table of Contents PART I Regulatory and Manufacturing Guidance 1 Chapter 1 Current Good Manufacturing Practice Considerations in Liquid Manufacturing 3 I. Introduction 3 II. Facilities 3 III. Equipment 3 IV. Raw Materials 4 V. Compounding 4 VI. Microbiological Quality 4 VII. Oral Suspensions 5 VIII. Product Specifications 5 IX. Process Validation 5 X. Stability 5 XI. Packaging 6 Chapter 2 Stability Testing of New Drug Substances and Products 7 I. Introduction 7 II. Drug Substance 7 A. General Case 8 B. Drug Substances Intended for Storage in a Refrigerator 8 C. Drag Substances Intended for Storage in a Freezer 8 D. Drug Substances Intended for Storage below -20°C 9 HI. Drag Product 10 A. General Case •' B. Drag Products Packaged in Impermeable Containers 11 C. Drag Products Packaged in Semipermeable Containers 11 D. Drag Products Intended for Storage in a Refrigerator 12 E. Drag Products Intended for Storage in a Freezer 13 F. Drag Products Intended for Storage below -20"C 13 IV Glossary 14 References 1() Chapter 3 Container Closure Systems '7 I. Introduction '7 A. Definitions '7 B. Current Good Manufacturing Practice, the Consumer Product Safety Commission, and Requirements on Containers and Closures 17 C. Additional Considerations 17 II. Qualification and Quality Control of Packaging Components 18 A. Description 21 B. Information about Suitability 21 C. Stability Data (Packaging Concerns) 22 D. Inhalation Drag Products 23 E. Injection and Ophthalmic Drag Products 23 F.
    [Show full text]
  • Monash Health Referral Guidelines – Gynaecology
    Monash Health Referral Guidelines (Incorporating Statewide Referral Criteria) GYNAECOLOGY EXCLUSIONS Services not offered In Vitro Fertilisation by Monash Health CONDITIONS CONTRACEPTIVE COUNSELLING MENSTRUAL MANAGEMENT Contraception Persistent, heavy menstrual bleeding Pregnancy Choices Bartholin's cysts / vaginal lesions Post-Menopausal bleeding Post-Coital bleeding DYSPLASIA Persistent or unexplained intermenstrual Dysplasia/Abnormal Cervical bleeding Screening Test Fibroids Vulval ulcers Vulval disorders PELVIC FLOOR/UROGYNAECOLOGY Genital warts Pelvic organ prolapse Urinary incontinence Recurrent UTI’s GYNAECOLOGY ENDOSCOPY Ovarian and other adnexal pathology Dyspareunia REPRODUCTIVE MEDICINE Pelvic Inflammatory disease Infertility Persistent pelvic pain Amenorrhea Male infertility Recurrent miscarriages GYNAECOLOGY ONCOLOGY Tubal & vasectomy reversal Cancer of the cervix Endocrine problems (Polycystic Ovarian cancer Ovarian Syndrome) Gynae cancers -suspected and confirmed SEXUAL MEDICINE & THERAPY CLINIC Sexual & relationship counselling MENOPAUSE Turner 's Syndrome Cancer and menopause PAEDIATRIC & ADOLESCENT GYNAE Premature menopause Paediatric and Adolescent Gynaecology General menopause ENDOMETRIOSIS Endometriosis Head of unit: Program Director: Last updated: Professor Beverley Vollenhoven Associate Professor Ryan Hodges 06/02/2020 Monash Health Referral Guidelines (Incorporating Statewide Referral Criteria) GYNAECOLOGY PRIORITY For emergency cases please do any of the following: EMERGENCY - send the patient to the Emergency
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Anesthesia: the Good, the Bad, and the Elderly
    ANESTHESIA: THE GOOD, THE BAD, AND THE ELDERLY Item Type Electronic Thesis; text Authors Hansen, Madeline Citation Hansen, Madeline. (2020). ANESTHESIA: THE GOOD, THE BAD, AND THE ELDERLY (Bachelor's thesis, University of Arizona, Tucson, USA). Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 25/09/2021 08:05:26 Item License http://rightsstatements.org/vocab/InC/1.0/ Link to Item http://hdl.handle.net/10150/651023 ANESTHESIA: THE GOOD, THE BAD, AND THE ELDERLY By MADELINE JOLLEEN HANSEN ____________________ A Thesis Submitted to The Honors College In Partial Fulfillment of the Bachelors degree With Honors in Physiology THE UNIVERSITY OF ARIZONA M A Y 2 0 2 0 Approved by: ____________________________ Dr. Zoe Cohen Department of Physiology Table of Contents Page number(s) Abstract……………………………………………………………………………………………………..2 General History of Anesthesia.………………………………………………………………………….3-14 Prehistoric-200AD…………………………………………………………….………………....3-5 200AD- 1846 (historical surgery)…………………….………………………………………….5-8 1847-1992……………………...…………………….……………………………………...….9-14 Physiology of General Anesthesia………………………………………………………...…………...14-16 Understanding of anesthesia mechanism…………………………………………………………14 System impacts………………………………………………………………………………..15-16 Description
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]